other material
confidence high
sentiment neutral
materiality 0.50
Aclaris Therapeutics enters into new at-the-market equity offering agreement with Leerink and Cantor
Aclaris Therapeutics, Inc.
- Second Amended and Restated Sales Agreement with Leerink Partners and Cantor Fitzgerald for at-the-market common stock offerings.
- Commission of 3.0% of gross proceeds payable to agents; no minimum offering amount required.
- Replaces prior $100M ATM agreement dated February 27, 2025; new agreement has no stated maximum.
- Shares sold under existing Form S-3 registration statement; Company retains discretion on timing and size.